PetCaseFinder

Peer-reviewed veterinary case report

Liver enzyme changes in dogs treated with fluconazole for lung fungal

By Berlin, Dena et al.·Published in Frontiers in veterinary science·2024·Department of Specialty Medicine, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Serial evaluation of liver enzyme activities in dogs with pulmonary coccidioidomycosis administeredfluconazole.

Species:
dog

Plain-English summary

A group of 32 dogs diagnosed with pulmonary coccidioidomycosis, a fungal infection affecting the lungs, were treated with fluconazole, a common antifungal medication. During the treatment, about half of the dogs showed mild increases in liver enzymes, specifically alkaline phosphatase (ALP) and alanine transaminase (ALT). These changes were not linked to factors like age, weight, or the dosage of fluconazole. Fortunately, the liver enzyme elevations were mild and did not lead to serious health issues, suggesting that while monitoring liver function is important, fluconazole can be safely used in these cases.

People also search for: dog lung infection treatment · fluconazole side effects in dogs · elevated liver enzymes in dogs treatment

Abstract

Pulmonary coccidioidomycosis is a relatively common fungal disorder in dogs that have lived in or traveled to endemic regions and fluconazole is a common antifungal treatment. Liver enzymopathy can occur with fluconazole administration, but the frequency of occurrence nor potentially associative factors have been explored in dogs with pulmonary coccidioidomycosis. Therefore, our objectives were to describe the occurrence and magnitude of liver enzyme activity (LEA) elevation in dogs with pulmonary coccidioidomycosis during treatment withfluconazole and identify variables associated with liver enzymopathy. This was a retrospective observational study that analyzed serum biochemical data obtained from a separate prospective study that included 32 client-owned dogs with newly diagnosed pulmonary coccidioidomycosis from October 2020 to February 2021.fluconazole administration (median dosage: 16.2&#x2009;mg/kg/day) was initiated after diagnosis and dogs were evaluated once every 3&#x2009;months thereafter until remission or for a maximum of 12&#x2009;months. Recorded biochemical parameters at each visit (including baseline) included alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT). Magnitude of increased LEA was based on the fold increase above the upper limit of the reference interval and defined as mild (<5&#xd7;), moderate (5-10&#xd7;) or severe (>10&#xd7;). Forty-seven percent (15/32) of dogs were documented to have elevations in one or more LEAs after initiation of fluconazole administration during the study period. Thirty-four percent and 25% of dogs had elevated ALP and ALT activities, respectively, at some point during treatment. Elevations in AST and GGT activities were rare. The magnitude of LEA elevation was mild in all cases. Logistic regression models did not identify associations between age, weight, sex, neutered status, prednisone administration, fluconazole dose or duration of treatment with the occurrence of liver enzymopathy. Approximately half of dogs with pulmonary coccidioidomycosis are expected to develop mild increases in activities of ALP and/or ALT with rare involvement of AST or GGT at some point during treatment with fluconazole up to 12&#x2009;months.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39315088/